NewLimit Blog

Home
Archive
About
New
Top
NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
 • 
Brian Armstrong
, 
Blake Byers
, 
Greg Johnson
, and 
Jacob C. Kimmel
April 2023 Progress Update
Overcoming a primary challenge
 • 
Jacob C. Kimmel
March 2023
March 2023 Progress Update - Live Event!
This time with live video
 • 
Jacob C. Kimmel
 and 
Brian Armstrong
February 2023 Progress Update
Screening at scale
 • 
Jacob C. Kimmel
February 2023
January 2023 Update
Bridging Atoms and Bits
 • 
Greg Johnson
January 2023
December 2022 Progress Update
(Calendar) Year in Review
 • 
Jacob C. Kimmel
December 2022
November 2022 Progress Update
Arrival at the starting line
 • 
Jacob C. Kimmel
November 2022
October 2022 Progress Update
Experiments in initialization
 • 
Jacob C. Kimmel
October 2022
We've added E. John Wherry to our Scientific Advisory Board
When we first started conceptualizing a T cell program at NewLimit, one of our dream researchers to work with was John Wherry. John is a developmental…
 • 
Jacob C. Kimmel
September 2022 Progress Update
Log-phase growth
 • 
Jacob C. Kimmel
September 2022
August 2022
Developing reprogramming therapies
Engineering a new class of medicines inspired by the biology development & regeneration
 • 
Jacob C. Kimmel
© 2023 NewLimit Inc.
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing